KURAMOTO, GRACIELA BARRIOMATSUDA, MARGARETH M.N.OSSO JUNIOR, JOAO A.2016-08-032016-08-032016KURAMOTO, GRACIELA BARRIO; MATSUDA, MARGARETH M.N.; OSSO JUNIOR, JOAO A. Compartmental and dosimetric studies of anti-CD20 labeled with sup(188)Re. <b>Journal of Radioanalytical and Nuclear Chemistry</b>, v. 309, n. 3, p. 1029-1035, 2016. DOI: <a href="https://dx.doi.org/10.1007/s10967-016-4703-y">10.1007/s10967-016-4703-y</a>. Disponível em: http://repositorio.ipen.br/handle/123456789/26526.0236-5731http://repositorio.ipen.br/handle/123456789/26526Radioimmunotherapy has the potential to deliver lethal radiation energy directly to malignant cells via targeting of radioisotope-conjugated monoclonal antibodies (MAbs) to specific antigens. Rituximab (RTX) is specifically targeted against CD20, a surface antigen expressed by B-lymphocytes. The use of 188Re from a 188W/188Re generator system represents an alternative radionuclide for therapy. Rhenium has chemical properties similar to technetium and both can be conjugated to antibodies using similar chemistry methods. The objective of this work is to prove the usefulness of this radiopharmaceutical based on dosimetric and pharmacokinetic studies that are also required by the Brazilian Regulatory Agency.1029-1035openAccesstherapylymphomasrhenium 188dosimetrylabelled compoundslymphocytesradiopharmaceuticalspharmacologyantibodiesCompartmental and dosimetric studies of anti-CD20 labeled with sup(188)ReArtigo de periódico330910.1007/s10967-016-4703-yhttps://orcid.org/0000-0002-6672-1631https://orcid.org/0000-0003-4455-348643.10